Intravitreal ranibizumab in the treatment of choroidal neovascular membrane secondary to punctate inner choroidopathy.

摘要

Punctate inner choroidopathy is a rare, idiopathic posterior uveitis that usually develops in young, myopic females. Choroidal neovascularization (CNV) and sub-retinal fibrosis are common complications in patients with punctate inner choroidopathy and are the major cause of vision loss. Treatment options for secondary CNV include systemic and intraocular steroids, photocoagula-tion, photodynamic therapy, and sub retinal surgery. More recently, intravitreal bevacizumab, an antivascular endo-thelial growth factor (anti-VEGF) agent, has been described with beneficial results. For the first time, we report the effectiveness of ranibizumab in the management of CNV associated with punctate inner choroidopathy.